The effect of early life events on glucose levels in first-episode psychosis.

Autor:	Garcia-Rizo C; Barcelona Clínic Schizophrenia Unit, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Cabrera B; Barcelona Clínic Schizophrenia Unit, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain., Bioque M; Barcelona Clínic Schizophrenia Unit, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Mezquida G; Barcelona Clínic Schizophrenia Unit, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Lobo A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Medicine and Psychiatry, University of Zaragoza, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain., Gonzalez-Pinto A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Hospital Universitario de Alava, Servicio de Psiquiatría, BIOARABA, University of the Basque Country, Vitoria, Spain., Diaz-Caneja CM; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain., Corripio I; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Vieta E; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, Barcelona, Spain., Baeza I; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Child and Adolescent Psychiatry and Psychology Department, Hospital Clinic of Barcelona, Institute of Neurosciences, University of Barcelona, Barcelona, Spain., Garcia-Portilla MP; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Psychiatry, University of Oviedo, Oviedo, Spain. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Gutierrez-Fraile M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Psychiatry, Araba University Hospital, University of the Basque Country (UPV/EHU), Vitoria, Spain.; Neurosciences Department, Araba University Hospital, University of the Basque Country (UPV/EHU), Vitoria, Spain., Rodriguez-Jimenez R; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Instituto de Investigacion Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain., Garriga M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, Barcelona, Spain., Fernandez-Egea E; Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon, United Kingdom., Bernardo M; Barcelona Clínic Schizophrenia Unit, Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Dec 05; Vol. 13, pp. 983792. Date of Electronic Publication: 2022 Dec 05 (Print Publication: 2022).
DOI:	10.3389/fendo.2022.983792
Abstrakt:	First episode of psychosis (FEP) patients display a wide variety of metabolic disturbances at onset, which might underlie these patients' increased morbidity and early mortality. Glycemic abnormalities have been previously related to pharmacological agents; however, recent research highlights the impact of early life events. Birth weight (BW), an indirect marker of the fetal environment, has been related to glucose abnormalities in the general population over time. We aim to evaluate if BW correlates with glucose values in a sample of FEP patients treated with different antipsychotics. Two hundred and thirty-six patients were included and evaluated for clinical and metabolic variables at baseline and at 2, 6, 12, and 24 months of follow-up. Pearson correlations and linear mixed model analysis were conducted to analyze the data. Antipsychotic treatment was grouped due to its metabolic risk profile. In our sample of FEP patients, BW was negatively correlated with glucose values at 24 months of follow-up [r=-0.167, p=0.037]. BW showed a trend towards significance in the association with glucose values over the 24-month period (F=3.22; p=0.073) despite other confounders such as age, time, sex, body mass index, antipsychotic type, and chlorpromazine dosage. This finding suggests that BW is involved in the evolution of glucose values over time in a cohort of patients with an FEP, independently of the type of pharmacological agent used in treatment. Our results highlight the importance of early life events in the later metabolic outcome of patients. Competing Interests: CG-R has received honoraria/travel support from Abbott, Adamed, Angelini, Cassen-Recordati, Janssen-Cilag and Lundbeck. MBi has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Ferrer, Janssen-Cilag, Lundbeck, Neuraxpharm, Otsuka, Pfizer and Sanofi. AL has received honorarium or travel support from Lundbeck and Sanofi. AG-P has received grants and served as consultant, advisor or CME speaker for the following entities: Almirall, AstraZeneca,Bristol-Myers Squibb, Cephalon, Eli Lilly, Glaxo-Smith-Kline, Janssen-Cilag, Ferrer, Johnson & Johnson, Lundbeck, Merck, Otsuka, Pfizer,Sanofi-Aventis, Servier, Shering-Plough, Solvay, and and Wyeth. CD-C has received honoraria from AbbVie, Sanofi, and Exeltis. IC has received research grants and served as consultant, advisor or speaker for the companies Otsuka and Ferrer. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, and Takeda. IB has received honoraria or travel support from Otsuka, and Angelini and Janssen. MG-P has been a consultant to and/or has received honoraria/grants from Angelini, Alianza Otsuka- Lundbeck, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, and SAGE Therapeutics. MG-F has been on the speakers/advisory board of Janssen-Cilag. RR-J has been a consultant for, spoken in activities of, or received grants from: Janssen Cilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste. MB has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of AB-Biotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Roviand Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. (Copyright © 2022 Garcia-Rizo, Cabrera, Bioque, Mezquida, Lobo, Gonzalez-Pinto, Diaz-Caneja, Corripio, Vieta, Baeza, Garcia-Portilla, Gutierrez-Fraile, Rodriguez-Jimenez, Garriga, Fernandez-Egea, Bernardo and PEPs GROUP.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu